Barclays Cuts Certara (NASDAQ:CERT) Price Target to $11.00

Certara (NASDAQ:CERT) had its target price trimmed by Barclays from $13.00 to $11.00 in a research report released on Thursday morning,Benzinga reports. The brokerage currently has an equal weight rating on the stock.

Several other equities analysts have also recently issued reports on the company. Stephens reissued an “overweight” rating and set a $17.00 target price on shares of Certara in a research note on Thursday, February 27th. William Blair reissued a “market perform” rating on shares of Certara in a research report on Thursday, February 27th. Finally, TD Cowen initiated coverage on shares of Certara in a report on Thursday, February 27th. They issued a “buy” rating and a $16.00 price objective for the company. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $15.50.

Certara Stock Up 22.8 %

Shares of NASDAQ:CERT opened at $12.91 on Thursday. The stock’s 50-day moving average is $11.61 and its 200 day moving average is $11.37. The company has a market cap of $2.08 billion, a PE ratio of -64.55, a P/E/G ratio of 9.29 and a beta of 1.64. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. Certara has a 1 year low of $8.64 and a 1 year high of $18.38.

Hedge Funds Weigh In On Certara

A number of institutional investors have recently added to or reduced their stakes in CERT. State Street Corp grew its position in shares of Certara by 3.4% in the 3rd quarter. State Street Corp now owns 3,679,699 shares of the company’s stock worth $43,089,000 after buying an additional 122,411 shares during the period. Jane Street Group LLC boosted its stake in Certara by 2.6% during the third quarter. Jane Street Group LLC now owns 147,393 shares of the company’s stock worth $1,726,000 after acquiring an additional 3,732 shares in the last quarter. Barclays PLC grew its holdings in Certara by 198.3% in the third quarter. Barclays PLC now owns 70,525 shares of the company’s stock worth $825,000 after purchasing an additional 46,880 shares during the period. 272 Capital LP purchased a new stake in Certara in the third quarter worth about $586,000. Finally, GAMMA Investing LLC increased its stake in shares of Certara by 442.2% during the fourth quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock valued at $90,000 after purchasing an additional 6,868 shares in the last quarter. Institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.